Neurocrine Biosciences Prices Public Offering of Common Stock at $8.10 per Share

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 9,500,000 shares of its common stock at a price to the public of $8.10 per share. The gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neurocrine, are expected to be approximately $77 million.

The offering is expected to close on or about January 24, 2012, subject to customary closing conditions.